AktiVax
Private Company
Funding information not available
Overview
Aktiv Medical Systems is a private, pre-revenue medical device company focused on addressing a significant gap in the autoinjector market for large-volume and high-viscosity biologic drugs. Its core technology, the PenPal® platform, utilizes a patented 'Direct Drive' compressed gas system applied directly to the drug container, enabling a simple, low-part-count design with demonstrated high reliability. The company aims to partner with pharmaceutical and biopharmaceutical firms to enable the subcutaneous delivery of next-generation biologics that are incompatible with existing autoinjector technologies, targeting underserved segments in vaccines, infectious diseases, and other therapeutic areas.
Technology Platform
PenPal® autoinjector platform featuring patented 'Direct Drive' compressed gas technology applied directly to the drug container for needle insertion, delivery, and retraction. Designed for high-viscosity biologics and dose volumes >2.25 mL with a simple, low-part-count architecture.
Opportunities
Risk Factors
Competitive Landscape
Aktiv competes in the autoinjector market dominated by large players like BD, Ypsomed, SHL Medical, and West Pharmaceutical. Its differentiation is a focused niche on high-volume (>2.25mL) and high-viscosity formulations, a segment where standard autoinjectors are ineffective, potentially reducing direct competition but requiring it to convince drug developers to adopt a new platform.